bioAffinity Technologies, Inc. (BIAF) Investor Relations Documents

bioAffinity Technologies, Inc. (BIAF) investor relations documents from the company's IR site: 1 presentation, 32 press releases; latest deck 2026-03-26. Read in-app with summaries. First-party data.

Spring 2026 Company Presentation View Presentation: bioAffinity Technologies (Nasdaq: BIAF) offers CyPath Lung, a noninvasive, AI-driven diagnostic test for early-stage lung cancer with 92% sensitivity.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-20Press releasebioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
2026-08-18Press releasebioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
2026-08-14Press releasebioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
2026-08-13Press releasebioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
2026-08-07Press releasebioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
2026-07-27Press releasebioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratifica
2026-07-22Press releasebioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and
2026-07-07Press releasebioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
2026-06-22Press releasebioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectiv
2026-06-18Press releasebioAffinity Technologies Announces Closing of $3.2 Million Offering
2026-06-17Press releasebioAffinity Technologies Announces Pricing of $3.2 Million Offering
2026-06-16Press releasebioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedic
2026-05-27Press releasebioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods
2026-05-12Press releasebioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2
Press releaseEarnings ReleaseHTML
2026-04-07Press releasebioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detectio
Quarterly reportbioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
2026-03-26PresentationSpring 2026 Company Presentation View Presentation
2026-03-13Press releasebioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
Press releasebioAffinity Technologies Reports Third Quarter 2025 Financial Results
Press releasebioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
Press releasebioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
Press releasebioAffinity Technologies Reports Second Quarter 2025 Results
Press releasebioAffinity Technologies Reports First Quarter 2025 Results
2025-03-31Press releasebioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
2024-11-14Press releasebioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
2024-08-14Press releaseEarnings ReleaseHTML
2024-05-15Press releaseEarnings ReleaseHTML
2024-04-01Press releaseEarnings ReleaseHTML
2023-11-14Press releaseEarnings ReleaseHTML
2023-08-14Press releaseEarnings ReleaseHTML
2023-05-15Press releaseEarnings ReleaseHTML
2023-03-31Press releaseEarnings ReleaseHTML
2022-11-14Press releaseEarnings ReleaseHTML

BIAF overview · BIAF earnings · BIAF financials · BIAF KPIs · BIAF documents · BIAF ownership · BIAF peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.